Subcutaneous vaccine administration – an outmoded practice

References

• Greenwood B. The contribution of vaccination to global health: past, present and future. Phil Trans R Soc Lond Biol Sci. 2014;369(1645):20130433. doi:10.1098/rstb.2013.0433.
   PubMed Web of Science ®Google Scholar
• Gowda C, Dempsey AF. The rise (and fall?) of parental vaccine hesitancy. Hum Vaccin Immunther. 2013;9(8):1755–62. doi:10.4161/hv.25085.
   PubMed Web of Science ®Google Scholar
• Salmon DA, Moulton H, Omer SB, DeHart MP, Stokley S, Hansey NA. Factors associated with refusal of childhood vaccines among parents of school-aged children: A case-control study. Arch Pediatr Adolesc Med. 2005;159(5):470–76. doi:10.1001/archpedi.159.5.470.
   PubMedGoogle Scholar
• Siddiqui M, Salmon D, Omer SB. Epidemiology of vaccine hesitancy in the United States. Hum Vaccin Immunother. 2013;9(12):2643–48. doi:10.4161/hv.27243.
   PubMed Web of Science ®Google Scholar
• Australian Immunisation Handbook. Canberra. Australia. 10th ed. Australian Government Department of Health. Vaccination procedures, Administration of vaccines, Route of administration; 2016 update. immunisationhandbook.health.gov.au/vaccination-procedures/administration-of-vaccines.
   Google Scholar
• Volk VK. Safety and effectiveness of multiple antigenic preparations in a group of free-living children. Am J Pub Health. 1949;39:1299–313. doi:10.2105/AJPH.39.10.1299.
   Web of Science ®Google Scholar
• Bauchner H. Evidence-based medicine: A new science or an epidemiologic fad. Pediatrics. 1999;103(5):1029–31. doi:10.1542/peds.103.5.1029.
   PubMed Web of Science ®Google Scholar
• Brockmeier AJ, Meizhi J, Przybyla P, Ananiadou S. Improving reference prioritization with PICO recognition. BMC Med Inform Decis Mak. 2019;19(1):256. doi:10.1186/s12911-019-0992-8.
   PubMed Web of Science ®Google Scholar
• Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–06. doi:10.1016/jclinepi.2010.07.015.
   PubMed Web of Science ®Google Scholar
• Wright JG, Plikaytis BD, Rose CE, Parker SD, Babcock J, Keitel W, El Sahly H, Poland GA, Jacobson RM, Keyserling HL. Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: A randomized trial. Vaccine. 2014;32(8):1019–28. doi:10.1016/j.vaccine.2013.10.039.
   PubMed Web of Science ®Google Scholar
• Marano N, Plikaytis BD, Martin SW, Rose C, Semenova VA. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months. JAMA. 2008;300(13):1532–43. doi:10.1001/jama.300.13.1532.
   PubMed Web of Science ®Google Scholar
• Pittman PR, Kim-Ahn G, Pifat DY, Coonan K, Gibbs P, Little S, Pace-Templeton JG, Myers R, Parker GW, Friedlander AM. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine. 2002;20(9–10):1412–20. doi:10.1016/s0264-410x(01)00462-5.
   PubMed Web of Science ®Google Scholar
• Pittman PR. Aluminum-containing vaccines associated adverse events: role of administration and gender. Vaccine. 2002;20(Suppl 3):S48–50. doi:10.1016/s0264-410x(02)00172-x.
   PubMed Web of Science ®Google Scholar
• Campbell JD, Clement KH, Wasserman SA, Donegan S, Chrisley L, Kotloff KL. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum Vaccin. 2007;3(5):205–11. doi:10.4161/hv.3.5.4459.
   PubMed Web of Science ®Google Scholar
• Pondo T, Rose CE, Martin SW, Kietel WA, Keyserling HC, Babcock J, Parker S, Jacobson RM, Poland GA, McNeil MM. Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC-AVA human clinical trial. Vaccine. 2014;32(28):3548–54. doi:10.1016/j.vaccine.2014.04.025.
   PubMed Web of Science ®Google Scholar
• Edelman R, Wasserman SA, Bodison SA, Perry JG, O’Donnoghue M, De Tolla LJ. Phase II safety and immunogenicity study of type F botulinum toxoid in adult volunteers. Vaccine. 2003;21(27–30):4335–47. doi:10.1016/s0264-410x(03)00460-2.
   PubMed Web of Science ®Google Scholar
• Carlsson R-M, Claesson BA, Kayhty H, Selstam U, Iwarson S. Studies on a Hib-tetanus toxoid conjugate vaccine: effects of co-administered tetanus toxoid vaccine, of administration route and of combined administration with an inactivated polio vaccine. Vaccine. 2000;18(5–6):468–78. doi:10.1016/x0264-410x(99)00238-8.
   Web of Science ®Google Scholar
• Volk VK, Top FH, Bunney WE. Significance of “cysts” following injections of antigens. Am J Public Health. 1954;44:1314–25. doi:10.2105/AJPH.44.10.1314.
   PubMed Web of Science ®Google Scholar
• Mark A, Carlsson R-M, Granstrom M. Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents. Vaccine. 1999;17(15–16):2067–72. doi:10.1016/s0264-410x(98)00410-1.
   PubMed Web of Science ®Google Scholar
• Rothstein EP, Kamiya H, Nii R, Matsuda T, Bernstein HH, Long SS, Hosbach PH, Meschievitz CK. Comparison of diphtheria-tetanus-two component acellular pertussis vaccines in United States and Japanese infants at 2, 4 and 6 months of age. Pediatrics. 1996;97:236–42.
   PubMed Web of Science ®Google Scholar
• Diggle L, Deeks JJ. Effect of needle length on incidence of local reactions to routine immunization in infants aged 4 months: randomized, controlled trial. BMJ. 2000;321:931–33. doi:10.1136/bmj.321.7266.931.
   PubMed Web of Science ®Google Scholar
• Diggle L, Deeks JJ, Pollard AJ. Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomized, controlled trial. BMJ. 2006;333:571–74. doi:10.1136/bmj.38906.704549.7C.
   PubMedGoogle Scholar
• Jackson LA, Starkovich P, Dunstan M, Yu O, Nelson J, Dunn J, Rees T, Zavitkovsky A, Maus D, Froeschle JE. Prospective assessment of the effect of needle length and injection site on the risk of local reaction to the fifth diphtheria-tetanus-acellular pertussis vaccination. Pediatrics. 2008;121(3):e646–52. doi:10.1542/peds.2007-1653.
   PubMed Web of Science ®Google Scholar
• Ipp MM, Gold R, Goldbach M, Maresky DC, Saunders N, Greenberg S, Davy T. Adverse reactions to diphtheria, tetanus, pertussis-polio vaccination at 18 months of age: effect of injection site and needle length. Pediatrics. 1989;83:679–82.
   PubMed Web of Science ®Google Scholar
• Holt LB. Bousfield G. P.T.A.P.: the present position. BMJ. 1949;1(4607):695–99. doi:10.1136/bmj.1.4607.695.
   PubMedGoogle Scholar
• Ragni MV, Lusher JM, Koerper MA, Manco-Johnson M, Krause DS. Safety and immunogenicity of subcutaneous hepatitis A vaccine in children with haemophilia. Haemophilia. 2000;6:98–103. doi:10.1046/j.1365-2516,2000.00386x.
   PubMed Web of Science ®Google Scholar
• Frosner G, Steffen R, Herzog C. Virosomal hepatitis A vaccine: comparing intradermal and subcutaneous with intramuscular administration. J Travel Med. 2009;16(6):413–19. doi:10.1111/j.1708-8305.2009.00351.x.
   PubMed Web of Science ®Google Scholar
• Fisch A, Cadilhac P, Vidor E, Prazuck T, Dublanchet A, Lafaix C. Immunogenicity and safety of new inactivated hepatitis A vaccine: a clinical trial with comparison of administration route. Vaccine. 1996;14(12):1132–36. doi:10.1016/0264-410x(96)00044-8.
   PubMed Web of Science ®Google Scholar
• Parent Du Chatelet I, Lang J, Schlumberger M, Vidor E, Soula G, Genet A, Standaert SM, Saliou P. Clinical immunogenicity and tolerance studies of liquid vaccines delivered by jet-injection and a new single-use cartridge (Imule®): comparison with standard syringe injection, Imule Investigators Group. Vaccine. 1997;15(4):449–58. doi:10.1016/s0264-410x(96)00173-9.
   PubMed Web of Science ®Google Scholar
• Ogawa M, Akine D, Sasahara T. Comparison of hepatitis B vaccine efficacy in Japanese students: a retrospective study. Environ Health Prev Med. 2019;24:80. doi:10.1186/s12199-019-0837-1.
   PubMed Web of Science ®Google Scholar
• Propst T, Propst A, Lhotta K, Vogel W, Konig P. Reinformed intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kidney Dis. 1998;32(6):1041–45. doi:10.1016/s0272-6386(98)70081-2.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Kuroki T, Kurai K, Iino S. Comparison of results of phase I studies with recombinant and plasma-derived hepatitis B vaccines and controlled study comparing intramuscular and subcutaneous injection of recombinant hepatitis B vaccine. J Infect. 1986;13(SupplA):53–60. doi:10.1016/s0163-4453(86)92698-8.
   PubMedGoogle Scholar
• Suzuki H, Iino S, Shiraki K, Akahane Y, Okamoto H, Domoto K, Mishiro S. Safety and efficacy of a recombinant yeast-derived pre-S2 + S containing hepatitis B vaccine (TGP-943): phase 1, 2 and 3 clinical testing. Vaccine. 1994;12(12):1090–96. doi:10.1016/0264-410X(94)90178-3.
   PubMed Web of Science ®Google Scholar
• Kishino H, Takahashi K, Sawata M, Tanaka Y. Immunogenicity, safety and tolerability of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young Japanese adults. Hum Vaccin Immunother. 2018;14(7):1773–78. doi:10.1080/21645515.2018.1452578.
   PubMed Web of Science ®Google Scholar
• de Lalla F, Rinaldi K, Santoro D, Pravettoni G. Immune response to hepatitis B vaccine given at different injection sites and by different routes: a controlled randomized study. Eur J Epidemiol. 1988;4(2):256–58. doi:10.1007/bf00144763.
   PubMed Web of Science ®Google Scholar
• Carpenter SL, Soucie JM, Presley RJ, Ragni MV, Wicklund BM, Silvey M, Davidson H. The hemophilia treatment center network investigators. Hepatitis B vaccination is effective by subcutaneous route in children with bleeding disorders: a universal data collection database analysis. Haemophilia. 2015;21(1):e30–43. doi:10.1111/hae.12569.
   Web of Science ®Google Scholar
• Vink P, Shiramoto M, Ogawa M, Eda M, Douha M, Heineman T, Lal H. Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥ 50 years when administered subcutaneously vs intramuscularly. Hum Vaccin Immunother. 2017;13(3):574–78. doi:10.1080/21645515.2016.1232787.
   PubMed Web of Science ®Google Scholar
• Ikeno D, Kimachi K, Kino Y, Harada S, Yoshida K, Tochihara S, Itamura S, Odagiri T, Tashiro M, Okada K. Immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection. Microbiol Immunol. 2010;54:81–88. doi:10.1111/j.1348-0421.2009.0091.x.
   PubMed Web of Science ®Google Scholar
• Hopf S, Garner-Spitzer E, Hofer M, Kundi M, Wiedermann U. Comparable immune responsiveness but increased reactogenicity after subcutaneous versus intramuscular administration of tick-borne encephalitis (TBE) vaccine. Vaccine. 2016;34(17):2027–34. doi:10.1016/j.vaccine.2015.12.057.
   PubMed Web of Science ®Google Scholar
• Bernstein DJ, Reap EA, Katen K, Watson A, Smith K, Norberg P, Olmsted RA, Hoeper A, Morris J, Negri S. Randomized, double-blind, phase I trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine. 2010;28(2):484–92. doi:10.1016/j.vaccine.2009.09.135.
   Web of Science ®Google Scholar
• Diez-Domingo J, Weinke T, Garcia de Lomas J, Meyer CU, Bertrand I, Eymin C, Thomas S, Sadorge C. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥ 50 years: A randomized non-inferiority clinical trial. Vaccine. 2015;33(6):789–95. doi:10.1016/j.vaccine.2014.12.024.
   PubMed Web of Science ®Google Scholar
• Koblin BA, Casapia M, Morgan C, Qin L, Wang ZM, Defawe OD, Baden L, Goepfert P, Tomaras GD, Montefiori DC. Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial. PloS ONE. 2011;6(9):e24517. doi:1371/journal.pone.0024517.
   PubMed Web of Science ®Google Scholar
• Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, Schmidt C, Gilmour J, Bogoshi M, Omosa-Manyonyi G, Dally L. Studies of a prophylactic HIV-I vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine. 2007;25(11):2120–27. doi:10.1016/j.vaccine.2006.11.016.
   PubMed Web of Science ®Google Scholar
• Enama ME, Ledgerwood JE, Novik L, Nason MC, Gordon IJ, Holman L, Bailer RT, Roederer M, Koup RA, Mascola JR. Phase I randomized clinical trial of VRC DNA and rAd5 HIV-I Vaccine delivery by intramuscular (IM), subcutaneous (SC) and intradermal (ID)administration (VRCOII). PloS ONE. 2014;9(3):e91366. doi:10.1371/journal.pone.0091366.
   PubMed Web of Science ®Google Scholar
• Lafeber AF, van der Klis FRM, Marzec AHJO, Labadie J, van Ommen R, Strieder TG, Berbers GAM MMR vaccine in 14 months old children, intramuscular versus subcutaneous administration RIVM Report 00002 001.
   Google Scholar
• Kuter BJ, Brown M, Wiedmann RT, Harzel J, Musey L. Safety and immunogenicity of M-M-RII (combination measles-mumps-rubella vaccine) in clinical trials of healthy children conducted between 1988 and 2009. Pediatr Infect Dis J. 2016;35(9):1011–20. doi:10.1097/INF,000000000001241.
   PubMed Web of Science ®Google Scholar
• Knuf M, Zepp F, Meyer CU, Habermehl P, Maurer L, Burow H-M, Behre U, Janssens M, Willems P, Bisanz H. Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella -varicella vaccine to children aged 11-21 months. Eur J Pediatr. 2010;169:925–33. doi:10.1007/s00431-010-1142-6.
   PubMed Web of Science ®Google Scholar
• Gillet Y, Habermehl P, Thomas S, Eymin C, Fiquet A. Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-Rvax Pro®) and varicella vaccine (VARIVAX®) by intramuscular or subcutaneous routes at separate injection sites: a randomized clinical trial. BMC Med. 2009;7(16). doi:10.1186/1741-7015-7-16.
   PubMedGoogle Scholar
• Haas H, Richard P, Eymin C, Fiquet A, Kuter B, Soubeyrand B. Immunogenicity and safety of intramuscular versus subcutaneous administration of a combined measles, mumps, rubella and varicella vaccine to children 12 to 18 months of age. Hum Vaccin Immunother. 2019;15(4):778–85. doi:10.1080/21645515.2018.1549452.
   PubMed Web of Science ®Google Scholar
• Pittman PR, McClain D, Quinn X, Coonan KM, Mangiafico J, Makuch RS, Morrill J, Peters CJ. Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase I dose escalation and route comparison study in humans. Vaccine. 2016;34(4):424–29. doi:10.1016/j.vaccine.1015.12.030.
   PubMed Web of Science ®Google Scholar
• Wilck MB, Seaman MS, Baden LR, Walsh SR, Grandpre LE, Devoy C, Giri A, Kleinjan J, Noble L, Stevenson K. Safety and immunogenicity of modified vaccinia Ankara (ACAM 3000): effect of dose and route of administration. J Infect Dis. 2010;201(9):1361–70. doi:10.1086/651561.
   PubMed Web of Science ®Google Scholar
• Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L, Schlereth B, Handley A, King L, Hülsemann V. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine. 2006;24(12):2065–70. doi:10.1016/j.vaccine.2005.11.022.
   PubMed Web of Science ®Google Scholar
• Frey SE, Newman FK, Kennedy JS, Sobek V, Ennis FA, Hill H, Yan LK, Chaplin P, Wollmar J, Chaitman BR, et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax® challenge. Vaccine. 2007;25(51):8562–73. doi:10.1016/j.vaccine.2007.10.017.
   PubMed Web of Science ®Google Scholar
• Seaman MS, Wilck MB, Baden LR, Walsh SR, Grandpre LE, Devoy C, Giri A, Noble L, Kleinjan J, Stevenson K. Effect of vaccination with modified Vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax. J Infect Dis. 2010;201(9):1353–60. doi:10.1086/651560.
   PubMed Web of Science ®Google Scholar
• Dennehy PH, Reisinger KS, Blatter MM, Veloudis PA. Immunogenicity of subcutaneous versus intramuscular Oka/Merck Varicella vaccination in healthy children. Pediatrics. 1991;88:604–07.
   PubMed Web of Science ®Google Scholar
• Fox JP, Kossobudzki SL, Fonseca da Cunha J. Field studies on the immune response to 17D yellow fever virus: relation to virus sub-strain, dose and route of inoculation. Am J Epidem. 1943;38:113–38. doi:10.1093/oxfordjournals.aje.a118875.
   Google Scholar
• Leung AK, Chiu AS, Siu TO. Subcutaneous versus intramuscular administration of haemophilus influenzae type b vaccine. J R Soc Health. 1989;109(2):71–73. doi:10.1177/146642408910900213.
   PubMedGoogle Scholar
• Cook IF, Barr I, Hartel G, Pond D, Hampson AW. Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine. 2006;24(13):2395–402. doi:10.1016/j.vaccine.2005.11.057.
   PubMed Web of Science ®Google Scholar
• Ruben FL, Jackson GG. A new subunit influenza vaccine: acceptability compared with standard vaccines and effect of dose on antigenicity. J Infect Dis. 1972;125(6):656–64. doi:10.1093/infdis/125.6.656.
   PubMed Web of Science ®Google Scholar
• Sanchez L, Matsuoka O, Inoue S, Inoue T, Meng Y, Nakama T, Kato K, Pandey A, Chang LJ. Immunogenicity and safety of high dose quadrivalent influenza vaccine in Japanese adults ≥ 65 years of age: a randomized controlled clinical trial. Hum Vaccin Immunother. 2020;16(4):858–66. doi:10.1080/21645515.2019.1677437.
   PubMed Web of Science ®Google Scholar
• Delafuente JC, Davis JA, Meuleman JR, Jones RA. Influenza vaccination and warfarin anticoagulation: A comparison of subcutaneous and intramuscular routes of administration in elderly men. Pharmacotherapy. 1998;18:631–36.
   PubMed Web of Science ®Google Scholar
• Ballester-Torrens MP, Acosta MA, Perez MTM, Perez BI, Brunet CJ, Doval GL, Garre MP. Intramuscular route for the administration of the anti flu vaccine in patients receiving oral anticoagulation therapy. Med Clin (Barc). 2005;124:291–94. doi:10.1157/13072321.
   PubMed Web of Science ®Google Scholar
• Casajuana J, Iglesias B, Fabregas M, Fina F, Valles J-A, Aragones R, Benitez M, Zabaleta E. Safety of intramuscular influenza vaccine in patients receiving anticoagulation therapy: a single-blinded, multi-centre randomized controlled trial. BMC Blood Disord. 2008;8:1. doi:10.1186/1471-2326-8-1.
   PubMedGoogle Scholar
• Laurichesse H, Gourdon F, Smits HL, Abdoe TH, Estavoyer JM, Rebika H, Pouliquen P, Catalina P, Dubray C, Beytout J. Safety and immunogenicity of subcutaneous or intramuscular administration of a monovalent inactivated vaccine against Leptospira interrogans serogroup Icterohaemorrhagiae in healthy volunteers. Clin Microbiol Infect. 2007;13(4):395–401. doi:10.1111/j.1469-0691.2007.01662.x.
   PubMed Web of Science ®Google Scholar
• Ruben FL, Froeschle JE, Meschievitz C, Chen K, George J, Reeves-Hoche MK, Pietrobon P, Bybel M, Livingood WC, Woodhouse L. Choosing a route of administration for quadrivalent meningococcal polysaccharide vaccine: intramuscular versus subcutaneous. Clin Infect Dis. 2001;32:170–72. doi:10.1086/317553.
   PubMed Web of Science ®Google Scholar
• Scheifele DW, Bjornson G, Boraston S. Local adverse effects of meningococcal vaccine. Can Med Assoc J. 1994;150:14–15.
   Web of Science ®Google Scholar
• Cook IF, Pond D, Hartel G. Comparative reactogenicity and immunogenicity of 23 valent pneumococcal vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine. 2007;25(25):4767–74. doi:10.1016/j.vaccine.2007.04.017.
   PubMed Web of Science ®Google Scholar
• Marshall H, Nolan T, Robertson D, Richmond P, Lambert S, Jacquet M, Schuerman L. A comparison of booster immunization with a combination DTPa-IPV vaccine or DTPa plus IPV separate injections when co-administered with MMR at age 4-6 years. Vaccine. 2006;24(35–36):6120–28. doi:10.1016/j.vaccine.2006.05.017.
   PubMed Web of Science ®Google Scholar
• Rupprecht CE, Hanlon CA, Hemachudha T. Rabies re-examined. Lancet Infect Dis. 2002;2(6):327–43. doi:10.1016/s1473-3099(02)00287-6.
   PubMed Web of Science ®Google Scholar
• Rabies vaccines: WHO position paper. Weekly epidemiological record No.32, 2010; 85: 309–20. http:/www.who.int/wer
   Google Scholar
• Silcock R, Crawford NW, Perrett KP. Subcutaneous nodules: an important adverse event following immunization. Expert Rev Vaccines. 2019;18(4):405–10. doi:10.1080/14760584.2019. 1586540.
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Jackson L, Patel SM, El Sahly HM, Spearman P, Rouphael N, Rudge TL, Hill H, Goll JB. Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults. Vaccine. 2014;32(47):6284–93. doi:10.1016/j.vaccine.2014.08.076.
   PubMed Web of Science ®Google Scholar
• Bergfors E, Bjorkelund C, Trollfors B. Nineteen cases of persistent pruritic nodules and contact allergy to aluminium after injection of commonly used aluminium-adsorbed vaccines. Eur J Pediatr. 2005;164(11):691–97. doi:10.1007/s00431-005-1704-1.
   PubMed Web of Science ®Google Scholar
• Bergfors E, Trollfors B, Inerot A. Unexpectedly high incidence of persistent itching nodules and delayed hypersensitivity to aluminium in children after the use of adsorbed vaccines from a single manufacturer. Vaccine. 2003;22(1):64–69. doi:10.1016/S0264-410X(03)00531-0.
   PubMed Web of Science ®Google Scholar
• Thierry-Carstensen B. Stellfeld. Itching nodules and hypersensitivity to aluminium after the use of adsorbed vaccines from SSI. Vaccine. 2004;22(15–16):1845. doi:10.1016/j.vaccine.2003.11.048.
   PubMed Web of Science ®Google Scholar
• Young B, Heath J. Nervous tissue, wheater’s functional histology. 4th ed. New York (NY): Churchill Livingstone; 2003. p. 140–41.
   Google Scholar
• Australian Government Department of Health, Therapeutic Goods Administration, Australian Clinical Trials Handbook, Clinical trial phases and stages, 12th October 2018.. www.tga.gov.au/book-page/clinical-trial-phases-and-stages
   Google Scholar
• Andrews JC, Schunemann HJ, Oxman AD, Pottie D, Meerpohl JJ, Coello PA, Rind D, Montori VM, Brito JP, Norris S. GRADE guidelines: 15. Going from evidence to recommendation – determinants of a recommendation’s direction and strength. J Clin Epidemiol. 2013;66(7):726–35. doi:10.1016/j.jclinepi.2013.02.003.
   PubMed Web of Science ®Google Scholar
• Inadvertent misadministration of meningococcal conjugate vaccine – United States. June-August 2005. MMWR Morb Mortal Weekly Report 2006; 55: 1016–17.
   Google Scholar
• Notes from the Field: Vaccine administration errors involving recombinant zoster vaccine – United States 2017-2018. MMWR. Morb Mortal Weekly Report. 2018;67(20):385–86. doi:10.15585/mmwr.mm6720a4.
   Google Scholar